Increased risk of MAFLD and liver fibrosis in inflammatory bowel disease independent of classic metabolic risk factors

ackground & Aims There is conflicting evidence regarding the prevalence of and risk factors for metabolic-associated fatty liver disease (MAFLD) in patients with inflammatory bowel disease (IBD). We aimed to determine MAFLD prevalence and risk factors in IBD patients. Methods Cross-sectional, ca...

Descripción completa

Detalles Bibliográficos
Autores: Rodríguez-Duque, Juan Carlos, Calleja, José Luis, Iruzubieta Coz, Paula, Hernández-Conde, Marta, Rivas-Rivas, Coral, Vera, María Isabel, García, María José, Pascual, Marta, Castro, Beatriz, García Blanco, Agustín, García Nieto, Enrique, Curiel Del Olmo, Soraya, Cagigal Cobo, María Luisa, López-Montejo, Lorena, Fernández-Lamas, Tatiana, Rasines, Laura, Fortea Ormaechea, José Ignacio, Vaqué Díez, José Pedro|||0000-0002-3913-2495, Frías, Yza, Rivero Tirado, Montserrat, Arias Loste, María Teresa, Crespo García, Javier
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universidad de Cantabria (UC)
Repositorio:UCrea Repositorio Abierto de la Universidad de Cantabria
Idioma:inglés
OAI Identifier:oai:repositorio.unican.es:10902/27778
Acceso en línea:https://hdl.handle.net/10902/27778
Access Level:acceso abierto
Palabra clave:MAFLD
Inflammatory Bowel Disease
Liver Fibrosis
Metabolic Syndrome
Descripción
Sumario:ackground & Aims There is conflicting evidence regarding the prevalence of and risk factors for metabolic-associated fatty liver disease (MAFLD) in patients with inflammatory bowel disease (IBD). We aimed to determine MAFLD prevalence and risk factors in IBD patients. Methods Cross-sectional, case-control study included all consecutive IBD patients treated at 2 different university hospitals. Controls were subjects randomly selected from the general population and matched by age, sex, type 2 diabetes status, and body mass index in a 1:2 ratio. MAFLD was confirmed by controlled attenuation parameter. Liver biopsies were collected when MAFLD with significant liver fibrosis was suspected. In addition, age- and fibrosis stage-paired non-IBD patients with biopsy-proven MAFLD served as a secondary control group. Results Eight hundred thirty-one IBD patients and 1718 controls were included. The prevalence of MAFLD and advanced liver fibrosis (transient elastography ≥9.7 kPa) was 42.00% and 9.50%, respectively, in IBD patients and 32.77% and 2.31%, respectively, in the general population (P < .001). A diagnosis of IBD was an independent predictor of MAFLD (adjusted odds ratio, 1.99; P < .001) and an independent risk factor for advanced liver fibrosis (adjusted odds ratio, 5.55; P < .001). Liver biopsies were obtained from 40 IBD patients; MAFLD was confirmed in all cases, and fibrosis of any degree was confirmed in 25 of 40 cases (62.5%). Body mass index and type 2 diabetes prevalence were significantly lower in IBD-MAFLD patients than in severity-paired patients with biopsy-proven MAFLD. Conclusions MAFLD and liver fibrosis are particularly prevalent in IBD patients, regardless of the influence of classic metabolic risk factors.

Similares en LA Referencia